First-line immunotherapy does not improve survival in metastatic lung cancer
Single or combination first-line immunotherapy does not significantly extend survival compared with chemotherapy in metastatic non small-cell lung carcinoma, trial results have shown.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer